Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer

Brachytherapy

Volumn 12, Issue 1, 2013, Pages 44-49

  Kotecha, Rupesh ^a   Yamada, Yoshiya ^a   Pei, Xin ^a   Kollmeier, Marisa A ^a   Cox, Brett ^a   Cohen, Gil'ad N ^a   Zaider, Marco ^a   Zelefsky, Michael J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Brachytherapy; High dose rate; IMRT; Prostate cancer; Radiation therapy; Toxicity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL ABSCESS; ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER CONTROL; CANCER SURVIVAL; DISTANT METASTASIS; DIVERTICULITIS; DYSURIA; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HEMATURIA; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; NOCTURIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION INJURY; RECTUM DISEASE; RECTUM HEMORRHAGE; RECURRENCE FREE SURVIVAL; URINARY FREQUENCY; URINARY URGENCY;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; COMBINED MODALITY THERAPY; HUMANS; MALE; MIDDLE AGED; NEW YORK; PREVALENCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84871766566     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2012.05.003     Document Type: Article

References (29)

1. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002, 53:1097-1105.
2. Zietman A.L., Bae K., Slater J.D., et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 2010, 28:1106-1111.
3. Peeters S.T., Heemsbergen W.D., Koper P.C., et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006, 24:1990-1996.
4. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8:475-487.
5. Kuban D.A., Levy L.B., Cheung M.R., et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?. Int J Radiat Oncol Biol Phys 2011, 79:1310-1317.
6. Deutsch I., Zelefsky M.J., Zhang Z., et al. Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT. Brachytherapy 2010, 9:313-318.
7. Mate T.P., Gottesman J.E., Hatton J., et al. High dose-rate afterloading 192-Iridium prostate brachytherapy: Feasibility report. Int J Radiat Oncol Biol Phys 1998, 41:525-533.
8. Eulau S., Van Hollebeke L., Cavanagh W., et al. High dose rate 192-Iridium brachytherapy in localized prostate cancer: Results and toxicity with maximum follow-up of 10 years. Int J Radiat Oncol Biol Phys 2000, 48(Suppl. 1):149. Abstract.
9. Galalae R.M., Kovács G., Schultze J., et al. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 2002, 52:81-90.
10. Astrom L., Pedersen D., Mercke C., et al. Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer. Radiother Oncol 2005, 74:157-161.
11. Deger S., Boehmer D., Roigas J., et al. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer. Eur Urol 2005, 47:441-448.
12. Hsu I., Chow J., Cabrera A.R., et al. Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancer. Brachytherapy 2005, 4:202-206.
13. Demanes D.J., Rodriguez R.R., Schour L., et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 2005, 61:1306-1316.
14. Chin Y., Bullard J., Bryant L., et al. High dose rate iridium-192 brachytherapy as a component of radical radiotherapy for the treatment of localised prostate cancer. Clin Oncol 2006, 18:474-479.
15. Yamada Y., Bhatia S., Zaider M., et al. Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer. Brachytherapy 2006, 5:157-164.
16. Thames H., Kuban D., Levy L., et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 2003, 57:929-943.
17. Stock R.G., Stone N.N., Cesaretti J.A., et al. Biologically effective dose values for prostate brachytherapy on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 2006, 64:527-533.
18. Kollmeier M.A., Pei X., Algur E., et al. A comparison of the impact of isotope (I-125 vs Pd-103) on toxicity and biochemical outcome following interstitial brachytherapy and external beam radiation therapy for clinically localized prostate cancer. Brachytherapy 2012, 11:271-276.
19. Zelefsky M.J., Pei X., Chou J.F., et al. Dose escalation for prostate cancer radiotherapy: Predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol 2011, 60:1133-1139.
20. Martinez A.A., Gonzalez J., Ye H., et al. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys 2011, 79:363-370.
21. Hoskin P.J., Motohashi K., Bownes P., et al. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: Initial results of a randomised phase three trial. Radiother Oncol 2007, 84:114-120.
22. Sathya J.R., Davis I.R., Julian J.A., et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005, 23:1192-1199.
23. Martinez A.A., Demanes D.J., Galalae R., et al. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Int J Radiat Oncol Biol Phys 2005, 62:1322-1331.
24. Demanes D.J., Brandt D., Schour L., Hill D.R. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation. Am J Clin Oncol 2009, 32:342-347.
25. Galalae R.M., Martinez A., Mate T., et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004, 58:1048-1055.
26. Pellizzon A.C., Salvajoli J., Novaes P., et al. Updated results of high-dose rate brachytherapy and external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO phoenix definition. Int Braz J Urol 2008, 34:293-301.
27. Viani G.A., Pellizzon A.C., Guimarães F.S., et al. High dose rate and external beam radiotherapy in locally advanced prostate cancer. Am J Clin Oncol 2009, 32:187.
28. Ágoston P., Major T., Fröhlich G., et al. Moderate dose escalation with single-fraction high-dose rate brachytherapy boost for clinically localized intermediate- and high-risk prostate cancer: 5-Year outcome of the first 100 consecutively treated patients. Brachytherapy 2011, 10:376-384.
29. Prada P.J., Mendez L., Fernández J., et al. Long-term biochemical results after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer. Risk 2012, 70:35.